Lineage Cell Therapeutics (LCTX) Capital Expenditures Growth (1y) (2011 - 2026)
Lineage Cell Therapeutics (LCTX) Capital Expenditures Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,320.50 Bn | 66,320.21 Bn | - | 38.18% |
| 2 | Nanobiotix | 1,933.82 Bn | 1,933.76 Bn | - | - |
| 3 | Akari Therapeutics | 1,022.34 Bn | 1,022.34 Bn | - | - |
| 4 | BeOne Medicines | 472.93 Bn | 468.14 Bn | 1.35 Bn | -27.93% |
| 5 | Vertex Pharmaceuticals | 122.22 Bn | 114.98 Bn | 2.59 Bn | 227.76% |
| 6 | Regeneron Pharmaceuticals | 69.96 Bn | 61.21 Bn | 3.31 Bn | 0.57% |
| 7 | Belite Bio | 62.66 Bn | 62.66 Bn | - | - |
| 8 | Argenx Se | 56.07 Bn | 50.89 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.60 Bn | 34.59 Bn | 959.66 Mn | 143.40% |
| 10 | Lineage Cell Therapeutics | 249.95 Mn | 187.24 Mn | 1.73 Mn | -43.30% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -43.30% |
| Dec 31, 2025 | -10.29% |
| Sep 30, 2025 | -11.69% |
| Jun 30, 2025 | -72.00% |
| Mar 31, 2025 | 155.26% |
| Dec 31, 2024 | 508.79% |
| Sep 30, 2024 | -155.40% |
| Jun 30, 2024 | -82.82% |
| Mar 31, 2024 | -75.16% |
| Dec 31, 2023 | 122.69% |
| Sep 30, 2023 | -51.40% |
| Jun 30, 2023 | 200.00% |
| Mar 31, 2023 | 232.61% |
| Dec 31, 2022 | -374.66% |
| Sep 30, 2022 | 429.63% |
| Jun 30, 2022 | -24.81% |
| Mar 31, 2022 | 318.18% |
| Dec 31, 2021 | 508.33% |
| Sep 30, 2021 | 125.00% |
| Jun 30, 2021 | 2,050.00% |